Stock Analysis
- Japan
- /
- Personal Products
- /
- TSE:4928
Noevir Holdings First Quarter 2025 Earnings: EPS: JP¥28.49 (vs JP¥29.45 in 1Q 2024)
Noevir Holdings (TSE:4928) First Quarter 2025 Results
Key Financial Results
- Revenue: JP¥16.8b (up 1.1% from 1Q 2024).
- Net income: JP¥973.0m (down 3.3% from 1Q 2024).
- Profit margin: 5.8% (down from 6.1% in 1Q 2024). The decrease in margin was driven by higher expenses.
- EPS: JP¥28.49 (down from JP¥29.45 in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Noevir Holdings Earnings Insights
Looking ahead, revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in Japan.
Performance of the Japanese Personal Products industry.
The company's shares are down 5.2% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Noevir Holdings that you should be aware of before investing here.
Valuation is complex, but we're here to simplify it.
Discover if Noevir Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4928
Noevir Holdings
Develops, produces, and sells cosmetics, pharmaceuticals, and health food products in Japan, China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, the United States, and Canada.